In a nutshell This trial was carried out to assess the effectiveness of EGFR-tyrosine kinase inhibitors (TKIs) with stereotactic body radiation therapy (SBRT) in advanced non-small-cell lung cancer (NSCLC). The authors found that TKIs plus SBRT improved the survival without disease worsening for these patients. Some background Lung cancer...
Read More
In a nutshell This review was carried out to analyze the effectiveness and safety of EGFR tyrosine kinase inhibitors (TKIs) plus chemotherapy (CT) versus EGFR-TKIs alone as a treatment for advanced non-small-cell lung cancer (NSCLC) that is EGFR-positive. The authors found that EGFR-TKIs and CT treatment improved survival for these patients while...
Read More
In a nutshell This article looked at the use of olmutinib (Olita) in the treatment of T790M-positive non-small cell lung cancer (NSCLC) that was previously unresponsive to a tyrosine kinase inhibitor (TKI). The authors concluded that olmutinib had clinical activity and manageable side effects in these patients. Some background NSCLC accounts for...
Read More
In a nutshell This study investigated the effectiveness of epidermal growth factor (EGF) ointment to treat skin side effects in patients with non-small cell lung cancer (NSCLC) receiving epidermal growth factor receptor (EGFR) inhibitor treatment. Researchers suggested that EGF ointment improves the outcomes and quality of life of these patients. Some...
Read More
In a nutshell This study compared dacomitinib (PF-00299804) to gefitinib (Iressa) as a first treatment for patients with EGFR-mutation positive non-small-cell lung cancer. The authors concluded that treatment with dacomitinib provided an improved overall survival compared to gefitinib. Some background Current cancer therapy heavily...
Read More
In a nutshell This trial examined the effectiveness and safety of osimertinib (Tagrisso) for treating patients with advanced non-small cell lung cancers that harbor T790M mutations. The authors concluded that the drug is promising in both safety and effectiveness at treating this type of cancer. Some background Non-small cell lung cancers...
Read More
In a nutshell This study aimed to determine whether EGFR-TKIs, in combination with surgery, is beneficial to patients with operable non-small-cell lung cancer (NSCLC). The authors concluded that patients with EGFR-mutation-positive NSCLC who were treated with both surgery and EGFR-TKIs showed improved survival compared to patients who underwent surgery...
Read More
In a nutshell This study aimed to determine the efficacy of a combination of the anticancer drugs afatinib (Gilotrif) and paclitaxel (Taxol) to treat non-small cell lung cancer (NSCLC), compared to chemotherapy alone. The study found that a combination of these drugs significantly improved progression free survival (PFS, time from treatment until...
Read More
In a nutshell This study compared the efficacy of antitumor drugs nivolumab (Opdivo) and docetaxel (Taxotere) in the treatment of advanced non-small-cell lung cancer (NSCLC). The study concluded that nivolumab has better activity in advanced nonsquamous NSCLC which express the ligand PD-L1 and has a safer toxicity profile overall than docetaxel. Some...
Read More
In a nutshell This study aimed to determine the safety and efficacy of a combination of the anticancer drugs afatinib (Gilotrif) and nimotuzumab (Theraloc) to treat kinase inhibitor resistant EGFR-mutant-NSCLC. The study found that a combination of these drugs had encouraging potential and an acceptable safety profile. Some background A mutation...
Read MoreIn a nutshell This article reviewed published data concerning treatment options for patients who develop resistance to EGFR targeting drugs, such as erlotinib (Tarceva). Some background The EGFR gene is responsible for building a specific protein needed by cancer cells to multiply. Mutations (changes) in this gene lead to more...
Read More
In a nutshell This study looked at Asian patients with non-small cell lung cancer (NSCLC) and compared the use of two drug regimens to see which was better. Some background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Some patients with NSCLC have a genetic mutation in a specific gene, the epidermal growth factor...
Read More
